#ASCO25: Takeda, Protagonist unveil data for rare blood disease drug
CHICAGO — Takeda and Protagonist Therapeutics are on the comeback trail with rusfertide, almost four years after the rare blood disease drug was put on a clinical hold because of safety issues in animal studies. ...
CHICAGO — Takeda and Protagonist Therapeutics are on the comeback trail with rusfertide, almost four years after the rare blood disease drug was put on a clinical hold because of safety issues in animal studies. ...
